Key statistics
As of last trade PTC Therapeutics Inc (PTCT:NSQ) traded at 44.36, -5.59% below its 52-week high of 46.98, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 43.81 |
---|---|
High | 44.85 |
Low | 43.67 |
Bid | 44.26 |
Offer | 44.47 |
Previous close | 43.23 |
Average volume | 689.45k |
---|---|
Shares outstanding | 77.13m |
Free float | 75.32m |
P/E (TTM) | -- |
Market cap | 3.33bn USD |
EPS (TTM) | -5.94 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 15:40 GMT.
More ▼
- PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
- CHMP Maintains Negative Opinion on Translarna™ Reexamination
- PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
More ▼